Results 1 to 10 of about 17,826,638 (304)
Some of the next articles are maybe not open access.
Alemtuzumab for B-cell chronic lymphocytic leukemia
Expert Review of Anticancer Therapy, 2008Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleoside analogs.
openaire +2 more sources
The normal counterpart to the chronic lymphocytic leukemia B cell
Best Practice & Research Clinical Haematology, 2007Chronic lymphocytic leukemia (CLL) is characterized by the monoclonal expansion of small mature-looking B cells that accumulate in the blood, marrow, and lymphoid organs, and have a remarkable phenotypic homogeneity. By definition, CLL cells co-express CD5 and CD23 with faint to undetectable amounts of monoclonal surface immunoglobulins (sIg).
Caligaris Cappio F +1 more
openaire +2 more sources
Angiogenesis is increased in B-cell chronic lymphocytic leukemia
Blood, 2001Aguayo and colleagues recently reported elevated levels of vascular endothelial growth factor (VEGF) in the cells of B-cell chronic lymphocytic leukemia (CLL).[1][1] When discussing the possible significance of the elevated VEGF levels in CLL, the authors cite their prior abstract in which ...
LoAnn Peterson, Ameet R. Kini, Neil Kay
openaire +2 more sources
Genetic Features of B‐Cell Chronic Lymphocytic Leukemia
Reviews in Clinical and Experimental Hematology, 2000The genetic features of B‐cell chronic lymphocytic leukemia CLL) are currently being reassessed by molecular cytogenetic techniques such as fluorescence in situ hybridization FISH). Conventional cytogenetic studies by chromosome banding are difficult in CLL mainly because of the low in vitro mitotic activity of the tumor cells, which leads to poor ...
S, Stilgenbauer, P, Lichter, H, Döhner
openaire +2 more sources
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia
Current Oncology Reports, 2017In recent years, a revolution in the management of chronic lymphocytic leukemia (CLL) has centered on the targeting of the B cell receptor (BCR) signaling pathway. Our improved understanding of the biology of cell signaling in CLL and the development of oral kinase inhibitors directed at the BCR pathway has led to the approval of two new agents and has
Jon E, Arnason, Jennifer R, Brown
openaire +2 more sources
Stereotyped B-cell receptors in chronic lymphocytic leukemia
Leukemia & Lymphoma, 2014Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome.
Andreas, Agathangelidis +3 more
openaire +2 more sources
Richter syndrome in B‐cell chronic lymphocytic leukemia
Pathology International, 2003Richter syndrome (RS) is well known as a secondary high‐grade lymphoma, mostly diffuse large B‐cell lymphoma (DLBCL) developed in patients with B‐cell chronic lymphocytic leukemia (B‐CLL). In this review, we describe clinicopathological, histological, immunophenotypical and genetic findings of RS.
Naoya, Nakamura, Masafumi, Abe
openaire +2 more sources
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2008A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.We investigated 1520 subjects who were 62 to 80 ...
Andy C, Rawstron +10 more
openaire +2 more sources
The neurologic complications of B-cell chronic lymphocytic leukemia
Neurology, 1997We performed a retrospective study to characterize the type, frequency, and timing of neurologic complications in patients with B-cell chronic lymphocytic leukemia (B-CLL). We reviewed 962 total charts with a median follow-up time of 57.5 months. There were 109 cases (11.3%) of neurologic complications, including 69 cases (7.2%) of herpes zoster ...
J H, Bower +3 more
openaire +2 more sources
Trisomy 8 in B-cell chronic lymphocytic leukemia
Cancer Genetics and Cytogenetics, 2008Association between trisomy 8 and myeloid disorders/malignancies has been well documented. We report on two patients with a known history of B-cell chronic lymphocytic leukemia (B-CLL) with bone marrow involvement. In addition to the classic B-CLL cytogenetic abnormalities in one of the patients, both showed a trisomy 8 clone in their bone marrow ...
Olga, Pozdnyakova +4 more
openaire +2 more sources